Sign In
Buy CNTB
$2.02
-0.0700 (-3.35%)
At Close: Jul 31, 2026
Connect Biopharma to Participate at the Jefferies Virtual China Biotech Summit
08:00am, Tuesday, 19'th Oct 2021
SAN DIEGO, CA and TAICANG, SUZHOU, China, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect Biopharma" or the “Company”), a global clinical-stage biopha
Connect Biopharma Provides Business Update and Reports First Half 2021 Financial Results
04:05pm, Tuesday, 31'st Aug 2021
- On Track to Report CBP-201 Phase 2B Top-Line Data Evaluating Moderate-to-Severe Atopic Dermatitis (AD) in Q4 of 2021 -
Connect Biopharma to Host First Half 2021 Financial Results Conference Call on September 1, 2021
08:00am, Wednesday, 25'th Aug 2021
SAN DIEGO and TAICANG, SUZHOU, China, Aug. 25, 2021 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect Biopharma" or the “Company”), a global clinical-stage biopharmac
Connect Biopharma Hires General Counsel & Chief Compliance Officer and Appoints a New Board Member
04:05pm, Monday, 23'rd Aug 2021
TAICANG, SUZHOU, China and SAN DIEGO, Aug. 23, 2021 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect Biopharma" or the “Company”), a global clinical-stage biopharmac
Connect Biopharma to Participate at the Jefferies Virtual Healthcare Conference
08:00am, Wednesday, 26'th May 2021
SAN DIEGO and TAICANG, SUZHOU, China, May 26, 2021 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect Biopharma" or the “Company”), a global clinical-stage biopharmace
Development program exploring the potential of CBP-174 in the treatment of chronic inflammatory pruritus
Week In Review: Genscript And Its Legend Bio Subsidiary Raise $1 Billion From Hillhouse
02:52pm, Sunday, 16'th May 2021
Genscript raised more than $1 billion from Hillhouse Capital in several different investments, including a $500 million commitment to Genscript's Legend Biotech CAR-T subsidiary. Shanghai Fosun Pharma
Connect Biopharma Completes Enrollment of CBP-201 Global Phase 2 Clinical Trial in Moderate-to-Severe Atopic Dermatitis
08:00am, Thursday, 08'th Apr 2021
SAN DIEGO and TAICANG, China, April 08, 2021 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect Biopharma" or the “Company”), a global clinical-stage biopharmaceutical
Deutsche Bank Appointed as Depositary Bank for the Sponsored American Depositary Receipt Program of Connect Biopharma Holdings Limited
05:45pm, Thursday, 25'th Mar 2021
NEW YORK--(BUSINESS WIRE)--Deutsche Bank announced today its appointment as depositary bank for the Nasdaq-listed American Depositary Receipt program of Connect Biopharma Holdings Limited. Connect Bio
US IPO Weekly Recap: The IPO Market Heats Up In An 11 IPO Week
11:43am, Sunday, 21'st Mar 2021
The IPO market stayed busy this past week, with 11 IPOs raising $3.0 billion. New filers continued to fill the IPO pipeline, with 8 IPOs and 46 SPACs submitting initial filings.
Qiming's Portfolio Company Connect Biopharma Lists on Nasdaq
09:00pm, Friday, 19'th Mar 2021
SHANGHAI, March 19, 2021 /PRNewswire/ -- Qiming Venture Partners' portfolio company Connect Biopharma today listed on the Nasdaq with the stock code "CNTB". The issue price is US$ 17.00/ADS.
